BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3352759)

  • 1. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
    Ozols RF; Masuda H; Hamilton TC
    NCI Monogr; 1988; (6):159-65. PubMed ID: 3352759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
    Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
    Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
    Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
    Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
    Peters RH; Jollow DJ; Stuart RK
    Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
    Goddard P; Valenti M; Kelland LR
    Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
    Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation response of drug-resistant variants of a human breast cancer cell line: the effect of glutathione depletion.
    Lehnert S; Greene D; Batist G
    Radiat Res; 1990 Nov; 124(2):208-15. PubMed ID: 2247601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
    Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
    Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
    Xu BH; Gupta V; Singh SV
    Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
    Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
    Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intercellular transfer of drug resistance.
    Frankfurt OS; Seckinger D; Sugarbaker EV
    Cancer Res; 1991 Feb; 51(4):1190-5. PubMed ID: 1997161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.